Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
02407 GAUSH MEDITECH
RT Nominal unchange10.240 0.000 (0.000%)
高視醫療科技有限公司
GAUSH MEDITECH LTD
Financial Year (D/M)01/01 - 31/12
Listing Date12/12/2022
Listing Price (HKD)51.400
Market Cap (HKD)1.514 Billions
Shares Capital
Issued Share Capital147,887,869
Market Value Indicator (Latest)
Year (Currency)2024/06 - Interim (RMB)
EPS (RMB)19.000 cts
DPS (RMB)0.000 cts
Divpayout Ratio (%)--
Cashflowper Share ($)--
BNV (RMB)10.411 dollar
Market Value Indicator (Year)
Peratio8.1
Yield (%)10.742
Pricetobook Ratio0.833
Remarks:  Real time quote last updated: 22/11/2024 08:32
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service.
Security Code
Company Name (Chi/Eng/Keywords)
Industry
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.